Literature DB >> 26294077

[Pharmacological aspects of pain research in Germany].

E Niederberger1, R Kuner2, G Geißlinger3.   

Abstract

In spite of several approved analgesics, the therapy of pain still constitutes a challenge due to the fact that the drugs do not exert sufficient efficacy or are associated with severe side effects. Therefore, the development of new and improved painkillers is still of great importance. A number of highly qualified scientists in Germany are investigating signal transduction pathways in pain, effectivity of new drugs and the so far incompletely investigated mechanisms of well-known analgesics in preclinical and clinical studies. The highlights of pharmacological pain research in Germany are summarized in this article.

Entities:  

Keywords:  Analgesics; Anti-inflammatory agents, non-steroidal; Ion channels; Neurotransmitters; Opioids

Mesh:

Substances:

Year:  2015        PMID: 26294077     DOI: 10.1007/s00482-015-0042-0

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  91 in total

1.  Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB.

Authors:  E Niederberger; I Tegeder; G Vetter; A Schmidtko; H Schmidt; C Euchenhofer; L Bräutigam; S Grösch; G Geisslinger
Journal:  FASEB J       Date:  2001-07       Impact factor: 5.191

2.  Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model.

Authors:  Wolfgang Koppert; Harald Ihmsen; Nicole Körber; Andreas Wehrfritz; Reinhard Sittl; Martin Schmelz; Jürgen Schüttler
Journal:  Pain       Date:  2005-09-09       Impact factor: 6.961

3.  Essential role of the synaptic vesicle protein synapsin II in formalin-induced hyperalgesia and glutamate release in the spinal cord.

Authors:  Achim Schmidtko; Domenico Del Turco; Ovidiu Coste; Corina Ehnert; Ellen Niederberger; Peter Ruth; Thomas Deller; Gerd Geisslinger; Irmgard Tegeder
Journal:  Pain       Date:  2005-05       Impact factor: 6.961

4.  A role for endocannabinoids in indomethacin-induced spinal antinociception.

Authors:  Hans Gühring; May Hamza; Marina Sergejeva; Mehmet Ates; Carolin E Kotalla; Catherine Ledent; Kay Brune
Journal:  Eur J Pharmacol       Date:  2002-11-15       Impact factor: 4.432

5.  Peripheral calcium-permeable AMPA receptors regulate chronic inflammatory pain in mice.

Authors:  Vijayan Gangadharan; Rui Wang; Bettina Ulzhöfer; Ceng Luo; Rita Bardoni; Kiran Kumar Bali; Nitin Agarwal; Irmgard Tegeder; Ullrich Hildebrandt; Gergely G Nagy; Andrew J Todd; Alessia Ghirri; Annette Häussler; Rolf Sprengel; Peter H Seeburg; Amy B MacDermott; Gary R Lewin; Rohini Kuner
Journal:  J Clin Invest       Date:  2011-03-07       Impact factor: 14.808

6.  Effects of COX inhibition on experimental pain and hyperalgesia during and after remifentanil infusion in humans.

Authors:  Harald Lenz; Johan Raeder; Tomas Draegni; Fridtjof Heyerdahl; Martin Schmelz; Audun Stubhaug
Journal:  Pain       Date:  2011-03-10       Impact factor: 6.961

7.  Peripheral and central antihyperalgesic effects of diclofenac in a model of human inflammatory pain.

Authors:  Maria Burian; Irmgard Tegeder; Maic Seegel; Gerd Geisslinger
Journal:  Clin Pharmacol Ther       Date:  2003-08       Impact factor: 6.875

8.  Activation of TRPV1 contributes to morphine tolerance: involvement of the mitogen-activated protein kinase signaling pathway.

Authors:  Yong Chen; Christian Geis; Claudia Sommer
Journal:  J Neurosci       Date:  2008-05-28       Impact factor: 6.167

9.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

Authors:  Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

Review 10.  Mode of action of cannabinoids on nociceptive nerve endings.

Authors:  Michaela Kress; R Kuner
Journal:  Exp Brain Res       Date:  2009-03-22       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.